WG
ZVRA icon

Winton Group’s Zevra Therapeutics ZVRA Stock Holding History

Winton Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
24,335
+8,001
+49% +$88.9K 0.01% 832
2026
Q1 		$152K Sell
16,334
-9,755
-37% -$87.9K 0.01% 1008
2025
Q4 		$234K Buy
26,089
+13,928
+115% +$132K 0.01% 799
2025
Q3 		$116K Buy
+12,161
New +$122K ﹤0.01% 688

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Winton Group's ZVRA Position: Q2 2026 in Review

Winton Group increased its Zevra Therapeutics (ZVRA) stake by 49% in Q2 2026, buying an estimated $88.9K and bringing the position to 24,335 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #832.

Winton Group first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. 106 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Winton Group held 24,335 shares of Zevra Therapeutics worth $349K as of Q2 2026.
  • Winton Group bought 8,001 Zevra Therapeutics shares in Q2 2026, an estimated $88.9K.
  • Zevra Therapeutics made up 0.01% of Winton Group's portfolio in Q2 2026, its #832 holding.
  • Winton Group first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 106 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.